Abbott diagnostics management
This article was originally published in The Gray Sheet
Executive Summary
Joseph Nemmers will lead the firm's worldwide diagnostics business following his appointment as senior VP-diagnostic operations Sept. 15. Formerly VP-global diagnostic commercial operations, Nemmers will report to Richard Gonzales, Medical Products Group president and COO. Nemmers, 48, replaces Thomas Brown, who retired last year after a failed FDA follow-up inspection of the company's Lake County, Ill. diagnostic manufacturing operations under a 1999 consent decree. In the interim, the unit has been headed by a senior management team (1"The Gray Sheet" June 17, 2002, p. 25)...
You may also be interested in...
Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
Costs related to Abbott's FDA consent decree could approach $1 bil. in lost revenue alone following a failed follow-up inspection of the company's Lake County, Illinois diagnostic manufacturing operations
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.